Advances in our understanding of molecular mechanisms of tumorigenesis have translated
into knowledge-based therapies directed against specific oncogenic signaling targets …

Simple Summary Despite great advances in cancer therapy, tumor heterogeneity continues
to be a great barrier for the successful treatment of cancer. It has long been established that …

Cancer cells enter a reversible drug-tolerant persister (DTP) state to evade death from
chemotherapy and targeted agents. It is increasingly appreciated that DTPs are important …

Tumor initiation and progression are somatic evolutionary processes driven by the
accumulation of genetic alterations, some of which confer selective fitness advantages to the …

Molecular routes to metastatic dissemination are critical determinants of aggressive cancers.
Through in vivo CRISPR–Cas9 genome editing, we generated somatic mosaic genetically …

Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal diseases, characterized
by a treatment-resistant and invasive nature. In line with these inherent aggressive …

Tumours are often composed of a multitude of malignant clones that are genomically
unique, and only a few of them may have the ability to escape cancer therapy and grow as …

Intratumour heterogeneity (ITH) has become an important focus of cancer research in recent
years. ITH describes the cellular variation that enables tumour evolution, including tumour …

Simple Summary Only 5% of all drug-related targets currently move from preclinical to
clinical in cancer, and just some of them achieve patient's bedside. Among others, intratumor …

Metastasis and tumor progression are the major cause of death in patients suffering from
pancreatic ductal adenocarcinoma. Tumor growth and especially dissemination are typically …